<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1561-2953</journal-id>
<journal-title><![CDATA[Revista Cubana de Endocrinología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Endocrinol]]></abbrev-journal-title>
<issn>1561-2953</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1561-29532020000300004</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Masa ósea y tratamiento esteroideo en pacientes con hiperplasia suprarrenal congénita]]></article-title>
<article-title xml:lang="en"><![CDATA[Bone mass and steroid treatment in patients with congenital adrenal hyperplasia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espinosa Reyes]]></surname>
<given-names><![CDATA[Tania M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leyva González]]></surname>
<given-names><![CDATA[Gisselle]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez Alonso]]></surname>
<given-names><![CDATA[Emma]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Endocrinología  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>31</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1561-29532020000300004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1561-29532020000300004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1561-29532020000300004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La terapia de reemplazo con glucocorticoides sigue siendo el paradigma de tratamiento en las formas clásicas de la hiperplasia suprarrenal congénita. Sus efectos sobre la mineralización ósea no están totalmente claros.  Objetivo:  Describir las variables relacionadas con la masa ósea en pacientes con HSC que reciben tratamiento esteroideo sustitutivo.  Método:  Se realizó un estudio descriptivo transversal que exploró variables clínicas, bioquímicas, hormonales y de mineralización óseaen 25 pacientes con hiperplasia suprarrenal congénita por déficit de 21OHasa y tratamiento esteroideo.  Resultados:  21 (84,0 %) femeninas, el mayor grupo correspondió a los adolescentes entre 10 y 19 años (52 %). Predominaron las formas clásicas con 22 pacientes (88,0 %), de ellas 13 (52 %) fueron perdedoras de sal, 9 virilizantes simples (36,0 %) y solo 3 (12,0 %) formas no clásicas. El esteroide más utilizado fue la hidrocortisona en 16 pacientes (64 %), a una dosis media de 22,10±12,00 mg diarios, correspondiendo con 17,09±5,71 mg/m2sc/día y como promedio llevaban 14,02±6,57 años de terapéutica sustitutiva. No se detectaron alteraciones del metabolismo fosfocálcico. La densidad y el contenido mineral óseo en columna y en fémur mostraron valores superiores en las formas no clásicas de la enfermedad, seguidos de la virilizante simple y finalmente los pacientes perdedores de sal, en ninguno de los casos con significación estadística.  Conclusiones:  Los pacientes con hiperplasia suprarrenal congénita del presente estudio mostraron en su mayoría una masa ósea conservada.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Glucocorticoid replacement therapy is still the treatment´s paradigm in the classic forms of congenital adrenal hyperplasia. Its effects on bone mineralization are not entirely clear.  Objective:  Describe bone mass-related variables in congenital adrenal hyperplasia patients receiving substitute steroid treatment.  Method:  A cross-sectional descriptive study was conducted exploring clinical, biochemical, hormonal and bone mineralization variables in 25 patients with congenital adrenal hyperplasia caused by 21OHase deficiency and steroid treatments.  Results:  21 women (84.0%); the largest group was of adolescents between the age of 10 and 19 years (52%).Classical forms predominated with 22 patients (88.0%), including 13 of them (52%) that were salt losers, 9 simple virilizers (36.0%) and only 3 (12.0%) of non-classical forms. The most commonly used steroid was hydrocortisone in 16 patients (64%), at an average dose of 22.10±12.00 mg daily, corresponding to 17.09±5.71 mg/m2sc/day and on average carried 14.02±6.57 years of substitute therapy. No alterations in the phosphocalcic metabolism were detected. Density and bone mineral content in the spinal column and femur showed higher values in non-classical forms of the disease, followed by simple virilizing and finally the salt loser patients, in none of the cases with statistical significance.  Conclusions:  Patients with congenital adrenal hyperplasia in this study showed mostly preserved bone mass.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[densidad mineral ósea]]></kwd>
<kwd lng="es"><![CDATA[hiperplasia suprarrenal congénita]]></kwd>
<kwd lng="es"><![CDATA[masa ósea conservada]]></kwd>
<kwd lng="en"><![CDATA[Bone mineral density]]></kwd>
<kwd lng="en"><![CDATA[congenital adrenal hyperplasia]]></kwd>
<kwd lng="en"><![CDATA[preserved bone mass]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Speiser]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Arlt]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Richard]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Auchus]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baskin]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Conway]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An Endocrine Society Clinical Practice Guideline]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2018</year>
<volume>103</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>4043-88</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canalis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bilezikian]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Angeli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Giustina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perspectives on glucocorticoid- induced osteoporosis]]></article-title>
<source><![CDATA[Bone]]></source>
<year>2004</year>
<volume>24</volume>
<page-range>593-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canalis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of glucocorticoid action in bone]]></article-title>
<source><![CDATA[Curr Osteoporos Rep]]></source>
<year>2015</year>
<volume>3</volume>
<page-range>98-102</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riehl]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucocorticoidd therapy may reduce bone density in congenital suprarrenal hiperplasia]]></article-title>
<source><![CDATA[Clin Endocrinol]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Omneya MO&#8218; Shaymaa E&#8218; Abohashaba]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Growth and bone mineral density in egypssian children it congenital suprarrenal hyperplasia on glucocorticoid replacement therapy. A single center study]]></source>
<year>2019</year>
<page-range>2-33</page-range><publisher-name><![CDATA[ESPE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Metwalley]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[El Saied]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bone mineral status in egypsian children with classic congenital suprarrenal hiperplasia A single center study from Upper Egypt]]></article-title>
<source><![CDATA[Indian endocrinol Metab]]></source>
<year>2014</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>700-4</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halper A&#8218; Sánchez B&#8218; Hodges J&#8218; Kelly]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bone mineral density and body composition in children with congenital suprarrenal hiperplasia]]></article-title>
<source><![CDATA[Clinical endocrinology]]></source>
<year>2018</year>
<volume>88</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>8-18</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carl]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Burtis]]></surname>
<given-names><![CDATA[ERA]]></given-names>
</name>
</person-group>
<collab>Tielz</collab>
<source><![CDATA[Fundamentals of Clinical Chemestry]]></source>
<year>2001</year>
<edition>Primera</edition>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burtis]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Ashwood]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Bruns]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<collab>Tietz</collab>
<source><![CDATA[Texbook of Clinical Chemestry and molecules diagnostics]]></source>
<year>2006</year>
<edition>Fourth</edition>
<publisher-loc><![CDATA[Philadelphia, WB ]]></publisher-loc>
<publisher-name><![CDATA[Saunders Co]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christiansen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Molgaard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Normal bone mineral content in young adults with congenital suprarrenal hiperplasia due to 21-hydroxilase deficiency]]></article-title>
<source><![CDATA[Hormone Research]]></source>
<year>2014</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>133-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<collab>Comité Nacional de Endocrinología</collab>
<article-title xml:lang=""><![CDATA[Consideraciones para una corticoterapia segura]]></article-title>
<source><![CDATA[Arch Argent Pediatr]]></source>
<year>2018</year>
<volume>116</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S71-S6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[MJA]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Composición corporal y factores relacionados, en pacientes con hiperplasia suprarrenal congénita]]></article-title>
<source><![CDATA[Rev Cubana de Endocrinol]]></source>
<year>2018</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>178-84</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleishman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ringelhein]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bone Mineral status in Children with Congenital Suprarrenal Hyperplasia]]></article-title>
<source><![CDATA[J Pediatr Endocrinol Metab]]></source>
<year>2014</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>227-35</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raizada]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Jyotsna]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Upadhyay]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Gupra]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bone mineral density in Young adult women with congenital suprarrenal hyperplasia]]></article-title>
<source><![CDATA[Indian Journal of Endocrinology and Metabolism]]></source>
<year>2016</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>62-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Callewaert]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Boonen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vanderschueren]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sex steroids and the male skeleton a tale of two hormones]]></article-title>
<source><![CDATA[Trends Endocrinol Metab]]></source>
<year>2010</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>89-95</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Río]]></surname>
<given-names><![CDATA[LCMF]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[CRLL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esteroides sexuales y metabolismo mineral óseo]]></article-title>
<source><![CDATA[Revista Ortho-tips]]></source>
<year>2010</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-30</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henwood]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Binkovitz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA["Update on pediatric bone health,"]]></article-title>
<source><![CDATA[The Journal of the American Osteopathic Association]]></source>
<year>2009</year>
<volume>109</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-12</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ceccato]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Barbot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Albiger]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zilio]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Toni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Luisetto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long- glucocorticoid effect on bone mineral density in patients with congenital suprarrenal hyperplasia due 21-hydroxilase deficiency]]></article-title>
<source><![CDATA[Europ Journal of endocrinology]]></source>
<year>2016</year>
<volume>175</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>101-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
